Displaying 581 - 600 of 1605
Monier Lifetile LLC, Boral Ltd., and Lafarge S.A, In the Matter of
The FTC charged that Boral Ltd. and LaFarge SA violated antitrust laws by establishing a joint venture, Monier Lifetile LLC, that combined their concrete roofing tile (CRT) manufacturing divisions. Boral and LaFarge are the two largest producers of CRT in the United States. To settle FTC charges that the joint venture would likely substantially reduce competition in the market for CRT, Monier Lifetile LLC agreed to sell production facilities in Arizona, California and Florida to CRH PLC.
Statement of Chairman Simons, Commissioner Phillips, and Commissioner Wilson In the Matter of Sycamore Partners II, L.P., Staples, Inc. and Essendant Inc.
Statement of Commissioner Chopra In the Matter of Sycamore Partners II, L.P., Staples, Inc. and Essendant Inc.
Statement of Commissioner Slaughter In the Matter of Sycamore Partners II, L.P., Staples, Inc. and Essendant Inc.
Statement of Commissioner Wilson In the Matter of Sycamore Partners II, L.P., Staples, Inc. and Essendant Inc.
FTC Imposes Conditions on Staples’ Acquisition of Office Supply Wholesaler Essendant Inc.
Sycamore Partners II, L.P., Staples, Inc. and Essendant Inc., In the Matter of
Office supply distributors Staples Inc. and Essendant Inc. have agreed to a settlement as part of the companies’ proposed $482.7 million merger in order to resolve Federal Trade Commission allegations that the deal may have harmed competition in the market for office supply products sold to small- and mid-sized businesses.
FTC Requests Public Comment on an Application from Praxair and Linde to Approve Sale of an Industrial Gases Plant to LyondellBasell
FTC Requests Public Comment on an Application from Praxair and Linde to Approve Sale of Industrial Gases Assets to Matheson Tri-Gas, Inc.
FTC Imposes Conditions in Joint Venture among Three Producers of PET Resin
FTC Requests Public Comment on an Application from Praxair and Linde to Approve Sale of Industrial Gases Assets to a Messer Group GmbH/CVC Capital Partners Joint Venture
FTC Approves Teva Petition to Reopen and Modify Decision and Order in Case Involving Watson Pharmaceuticals Inc.’s Acquisition of Actavis Inc.
Watson Pharmaceuticals / Actavis Inc., In the Matter of
The FTC required Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive. The settlement protects competition in the markets for 21 current and future generic drugs, used to treat a wide range of conditions ranging from hypertension and diabetes to anxiety and attention deficit hyperactivity disorder (ADHD).
There is a related federal proceeding and two related administrative proceedings:
Administrative Law Judge Upholds FTC’s Complaint Allegations that Merger of Major Titanium Dioxide Companies would have Harmed Competition
FTC Testifies before House Subcommittee on Regulatory Reform, Commercial and Antitrust Law on Competition Enforcement Activities and Policy Priorities
FTC Charges Executive Whose Company Owns New York Knicks, New York Rangers with Violations of U.S. Premerger Notification Requirements
FTC Approves Modified Final Order Imposing Conditions on Northrop Grumman’s Acquisition of Solid Rocket Motor Supplier Orbital ATK, Inc.
Displaying 581 - 600 of 1605